Want to see HK:6185 full AI Analyst Report?
Top Page
CanSino Biologics, Inc. Class H
(6185)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$27.00
▼(-39.92% Downside)
Action:Reiterated
Date:10/29/26
The score is held back primarily by weak cash conversion (negative free cash flow despite improved earnings) and bearish technical momentum (below key moving averages with negative MACD). A solid balance sheet and sharp recent revenue rebound provide some support, but the very high P/E meaningfully increases valuation risk.
Positive Factors
Revenue rebound
The strong TTM revenue rebound and renewed growth in 2024–2025 indicate recovering commercial demand and improved business traction. If this momentum persists, higher sales can support greater manufacturing utilization, broaden market reach, and provide a stronger base for future profitability.
Negative Factors
Negative free cash flow
Negative free cash flow means reported operating activity is not yet covering investment needs, limiting the cash available for strategic initiatives and balance-sheet strengthening. The persistence of negative free cash flow across prior years raises concern that revenue recovery may require continuing financial support.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The strong TTM revenue rebound and renewed growth in 2024–2025 indicate recovering commercial demand and improved business traction. If this momentum persists, higher sales can support greater manufacturing utilization, broaden market reach, and provide a stronger base for future profitability.
Read all positive factors
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.23B
Dividend Yield1.31%
Average Volume (3M)5.42M
Price to Earnings (P/E)632.6
Beta (1Y)1.29
Revenue Growth36.09%
EPS GrowthN/A
CountryHK
Employees1,134
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.12
Shares Outstanding132,670,900
10 Day Avg. Volume4,033,824
30 Day Avg. Volume5,420,673
Financial Highlights & Ratios
PEG Ratio-2.66
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$49.60Price Target Upside10.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.33
Revenue Forecast (FY)HK$1.44B
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola vir...
How the Company Makes Money
CanSino primarily makes money by selling vaccines and vaccine-related products to customers such as public health agencies, disease control organizations, and other healthcare procurement channels, generating revenue when vaccine doses are deliver...
CanSino Biologics, Inc. Class H Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
71
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.03B | 846.34M | 345.18M | 1.03B | 4.30B |
| Gross Profit | 899.75M | 681.82M | 601.91M | -876.02M | -186.61M | 3.00B |
| EBITDA | 43.36M | 60.98M | -163.84M | -1.65B | -1.30B | 1.87B |
| Net Income | 29.72M | 27.15M | -378.88M | -1.48B | -909.43M | 1.91B |
Balance Sheet | ||||||
| Total Assets | 6.84B | 7.18B | 7.96B | 9.32B | 11.47B | 11.87B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 2.65B | 3.20B | 4.12B | 5.95B | 7.78B |
| Total Debt | 929.08M | 1.29B | 2.01B | 2.70B | 2.70B | 1.37B |
| Total Liabilities | 1.84B | 2.05B | 3.05B | 4.03B | 4.22B | 3.33B |
| Stockholders Equity | 5.01B | 4.96B | 4.91B | 5.27B | 6.75B | 8.00B |
Cash Flow | ||||||
| Free Cash Flow | -63.56M | -152.83M | -626.42M | -1.53B | -2.96B | 811.42M |
| Operating Cash Flow | 95.95M | 32.49M | -168.79M | -916.25M | -1.89B | 2.01B |
| Investing Cash Flow | 949.86M | 355.36M | 3.96M | -449.65M | -1.19B | -2.53B |
| Financing Cash Flow | -533.05M | -703.03M | -334.18M | -7.58M | 854.60M | 1.56B |
CanSino Biologics, Inc. Class H Technical Analysis
Negative
44.94
Price Trends
30.16
Negative
26.77
Negative
29.70
Negative
Market Momentum
-0.97
Positive
37.78
Neutral
9.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Negative. The current price of 44.94 is above the 20-day moving average (MA) of 31.87, above the 50-day MA of 30.16, and above the 200-day MA of 29.70, indicating a bearish trend. The MACD of -0.97 indicates Positive momentum. The RSI at 37.78 is Neutral, neither overbought nor oversold. The STOCH value of 9.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6185.
CanSino Biologics, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$196.24B | 24.96 | 18.26% | 1.50% | 24.97% | 43.23% | |
60 Neutral | HK$18.13B | 143.19 | 1.43% | ― | -8.55% | -96.20% | |
56 Neutral | HK$14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$11.54B | -37.70 | -101.49% | ― | ― | ― | |
48 Neutral | HK$4.45B | -18.04 | -15.68% | ― | 237.19% | 61.28% | |
46 Neutral | HK$13.23B | 632.61 | 0.60% | 1.31% | 36.09% | ― |
* Healthcare Sector Average
HK:6185
CanSino Biologics, Inc. Class H
25.78
-20.48
-44.27%
HK:0013
HUTCHMED (China)
20.78
-2.48
-10.66%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
3.94
-1.24
-24.01%
HK:3692
Hansoh Pharmaceutical Group Company Limited
32.36
-2.77
-7.88%
HK:2627
Ab&B Bio-Tech CO., LTD. JS Class H
29.32
-10.98
-27.25%
HK:2575
Xuanzhu Biopharmaceutical Co., Ltd. Class H
8.60
-55.00
-86.48%
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics Posts Revenue Growth but Core Profit and Cash Flow Under Strain
Oct 27, 2026
CanSino Biologics Inc. has released its unaudited third quarterly report for the nine months ended 30 September 2026, prepared under Chinese Accounting Standards and filed as inside information in Hong Kong. The board and senior management state t...
CanSino Biologics Schedules Board Meeting to Approve Third-Quarter Results
Oct 14, 2026
CanSino Biologics Inc., a PRC-incorporated biopharmaceutical company listed in Hong Kong, develops and commercializes biological products and vaccines, and is overseen by a diversified board that includes executive, non-executive and independent d...
CanSino Biologics Grants Reserved Restricted Shares Under 2025 Incentive Scheme
Sep 16, 2026
CanSino Biologics Inc. has approved the grant of 287,400 reserved restricted A shares under its 2025 A Share Incentive Scheme to 19 participants who meet the grant conditions, at a grant price of RMB41.20 per share, compared with a closing market ...
CanSino Biologics Publishes Unaudited Interim Results for First Half of 2026
Aug 27, 2026
CanSino Biologics Inc. announced its unaudited interim results for the six months ended June 30, 2026, confirming that the figures comply with Hong Kong listing requirements for preliminary interim disclosures. The board and its audit committee ha...
CanSino Biologics Advances mRNA Platform and Forms Cancer Vaccine Alliance
Aug 26, 2026
CanSino Biologics Inc. has highlighted the development of its mRNA technology platform, which underpins its pipeline of mRNA preventive vaccines and therapeutic biologics. The company is pushing early-stage research on mRNA vaccines for glioblasto...
CanSino Wins NMPA Approval for New Tetanus Vaccine, Boosting Adult Vaccine Portfolio
Aug 20, 2026
CanSino Biologics Inc., a Hong Kong-listed Chinese vaccine developer, is broadening its product portfolio and market reach, with a particular focus on adult immunizations in Greater China. The company leverages advanced, animal-free production tec...
CanSino’s Td5cp Booster Wins Priority Review After NDA Acceptance in China
Aug 16, 2026
CanSino Biologics Inc. has announced that China’s National Medical Products Administration has accepted its new drug application for the Td5cp Adolescent and Adult vaccine. The product is a tetanus, reduced diphtheria and acellular pertussis...
CanSino Biologics Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
CanSino Biologics Inc. has scheduled a board meeting for August 27, 2026 to review and approve the interim financial results for the six months ended June 30, 2026, along with their planned publication. The board will also consider whether to reco...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.